Acute Care Therapeutics for Surgical Settings

Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings.

About Baudax Bio

We are committed to bringing meaningful therapeutic options to patients, healthcare providers, and payers.  We currently have multiple therapeutic candidates across early, mid and late-stage clinical development, including a FDA approved non-opioid therapy for use in the acute care setting.

About Us

Our Innovative Portfolio & Pipeline

On February 20, 2020, the FDA approved ANJESO (meloxicam) injection, for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.  Our product pipeline contains valuable therapeutic candidates for patients and healthcare providers in acute care settings.

ANJESO (meloxicam) injection

Product Portfolio

Latest News

Baudax Bio to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

View Press Release

Baudax Bio to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

View Press Release

Baudax Bio Announces Clinical Program Update for Neuromuscular Blocking Agents BX-1000, BX-2000 and BX-3000

View Press Release

Baudax Bio Reports Third Quarter 2021 Financial Results and Business Highlights

View Press Release

Baudax Bio to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021

View Press Release

Baudax Bio to Present at the NobleCon Pain Management Investor Forum

View Press Release

Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

View Press Release

Baudax Bio to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

View Press Release

Baudax Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

View Press Release

Baudax Bio Reports Second Quarter 2021 Financial Results and Highlights

View Press Release

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today